by Plasmid DNA is used extensively in the development of gene therapy and cell therapies for various diseases. It is a DNA molecule that is separate from or can exist independently of the chromosomal DNA within a living cell. Plasmids are frequently used as vectors for insertion of foreign DNA into host organisms. They are capable of autonomous replication in bacteria cells. Furthermore, as gene therapies and cell therapies have gained more interest in the treatment of cancers and other diseases, there has been a surge in demand for plasmid DNA that is driving the market growth. However, the manufacturing process of plasmid DNA requires advanced molecular biology techniques and experienced researchers. This has led major pharmaceutical and biotechnology companies to rely on contract manufacturing organizations for their plasmid DNA needs. Additionally, increasing investments by governments and private organizations into gene therapy research is expected to accelerate the demand.
The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the plasmid DNA manufacturing market is the development of advanced scalable manufacturing platforms that can produce plasmid DNA in large quantities at reduced costs. Companies are investing in automated plasmid production units with closed single-use systems that maximize yields and ensure sterility. Additionally, several novel approaches like non-viral, nanoparticle-based gene delivery are being researched which negates the need for plasmid DNA. However, they are still in early stages of development and plasmid DNA remains the gold standard for fundamental gene therapy research.
Porter’s Analysis
Threat of new entrants: The plasmid DNA manufacturing market requires high capital investments for establishing facilities, equipment and hiring specialized workforce which acts as a barrier for new entrants.
Bargaining power of buyers: The buyers have moderate to high bargaining power as there are several players operating in this market providing similar products.
Bargaining power of suppliers: The suppliers have low to moderate bargaining power as raw materials used in this market are commodity chemicals which are available from multiple suppliers.
Threat of new substitutes: There exists a low threat of substitutes as plasmids are irreplaceable reagents for various gene and cell therapies with no close substitutes available.
Competitive rivalry: The competition is high among the existing players to gain higher market share by expanding their production capacities and capabilities.
Key Takeaways
The global Plasmid DNA Manufacturing market is expected to witness high growth. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regional analysis comprises North America dominates the global market currently due to presence of key players, technological advancements and increasing expenditure on R&D. Asia Pacific is expected to be the fastest growing region over the forecast period with countries like China and India emerging as hubs of plasmid DNA manufacturing facilities.
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing. Key players are focusing on strategic collaborations and increasing their production capacities to cater to the growing demand for plasmids.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
